X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Immunome aims to utilize Atreca's APN-497444, a Glycan receptor inhibitor currently in the discovery stage, for the treatment of gastrointestinal cancers.
Lead Product(s): APN-497444
Therapeutic Area: Oncology Product Name: APN-497444
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Immunome
Deal Size: $12.5 million Upfront Cash: $5.5 million
Deal Type: Acquisition December 26, 2023
Details:
APN-346958 targets a novel RNA-binding protein which is tumor-reactive in at least 50% of samples for six tumor types evaluated, including colorectal, thyroid, head and neck, urothelial, melanoma and brain cancer.
Lead Product(s): APN-346958
Therapeutic Area: Oncology Product Name: APN-346958
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
ATRC-101 is a monoclonal antibody derived from an antibody identified using Atreca’s discovery platform. ATRC-101 is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.
Lead Product(s): ATRC-101,Pembrolizumab
Therapeutic Area: Oncology Product Name: ATRC-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Immunohistochemistry studies demonstrated tumor-selective binding of ATRC-101 to multiple non-autologous tumor tissues, and biochemical analyses indicate that it targets an extracellular, tumor-specific ribonucleoprotein (RNP) complex.
Lead Product(s): ATRC-101
Therapeutic Area: Oncology Product Name: ATRC-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
As part of the licensing agreement with Zymeworks, Atreca’s novel antibodies ATRC-301, will be conjugated using ZymeLink™, Zymeworks’ suite of proprietary cytotoxins, linkers, and conjugation technologies.
Lead Product(s): ATRC-301
Therapeutic Area: Oncology Product Name: ATRC-301
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Zymeworks
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 05, 2022
Details:
APN-850271 is an IgG antibody, Currently undergoing Preclinical phase target SARS-CoV-2-binding antibodies and had neutralizing activity against replication-competent SARS-CoV-2 in an initial screen.
Lead Product(s): APN-850271
Therapeutic Area: Infections and Infectious Diseases Product Name: APN-850271
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
Under the agreement, Gates MRI will lead the development of MAM01/ATRC-501 and receive commercial rights in GAVI-eligible countries located in malaria-endemic regions of the world, to advance its charitable purposes.
Lead Product(s): ATRC-501,MAM01
Therapeutic Area: Infections and Infectious Diseases Product Name: MAM01/ATRC-501
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2021
Details:
ATRC-101, which targets a novel tumor antigen and acts via a novel MOA in oncology, was well-tolerated at all doses evaluated in the study with no dose-limiting toxicities observed.
Lead Product(s): ATRC-101
Therapeutic Area: Oncology Product Name: ATRC-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 29, 2021
Details:
ATRC-101 has demonstrated robust anti-tumor activity as a single agent in multiple preclinical syngeneic tumor models, including one model in which PD-1 checkpoint inhibitors typically display limited activity.
Lead Product(s): ATRC-101
Therapeutic Area: Oncology Product Name: ATRC-101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
Under the terms of the agreement, the companies will engage in a three-year discovery program. Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.
Lead Product(s): T Cell Engaging Bispecific Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xencor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
